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Although the administration of dopamine precursor levodopa remains as the mainstay
for the treatment of Parkinson’s disease, long-term exposure to levodopa often causes
a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the
development of new therapeutic interventions to dampen levodopa-induced dyskinesias
and parkinsonian motor deficits is needed in the treatment of Parkinson’s disease.
Intracerebral brain infusion has the merit of being able to specifically deliver any drug
into any brain part. By using an intracerebral infusion system equipped with implantable,
programmable, and refillable pumps, we show herein that continuous intrastriatal
administration of memantine (MMT), which is a non-competitive N-methyl-D-aspartate
receptor antagonist, attenuates levodopa-induced dyskinesias and parkinsonian signs
in 6-hydroxydopamine-lesioned hemiparkinsonian mice that received daily levodopa
treatment. Corroborating the general thought that overactivation of the striatal
N-methyl-D-aspartate receptor function might generate levodopa-induced dyskinesias
and parkinsonism, our results suggest that a continuous intrastriatal MMT infusion
can be beneficial for the management of Parkinson’s disease with levodopa-induced
dyskinesias. Our study also provides indications for the prototypic use of pharmacological
deep-brain modulation through intracerebral infusion systems for treating medically
intractable movement disorders.
Keywords: intracerebral brain infusion, levodopa-induced dyskinesia, memantine, N-methyl-D-aspartate receptor,
Parkinson’s disease
INTRODUCTION
The administration of the dopamine precursor levodopa is a powerful tool for treating Parkinson’s
disease; however long-term exposure to levodopa often provokes abnormal involuntarymovements
(AIMs), referred to as levodopa-induced dyskinesias (LIDs) (1). LID is a major cause of disability
that occurs in >80% of Parkinson’s disease patients after 5 years of daily levodopa treatment (2).
Although electrical deep brain stimulation can produce a striking impact on Parkinson’s disease
with LIDs, its therapeutic efficacy for the quality of life has usually fallen below preoperative levels
during long-term follow-up (3). Therefore, the development of alternative or adjunct therapeutic
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interventions for overcoming both LIDs and “OFF”-period
symptoms is a pressing challenge in the treatment of
Parkinson’s disease.
Parkinsonian symptoms result from striatal dysfunction
caused by an imbalance between dopamine and glutamate
transmissions (4, 5). The dysregulation of corticostriatal
glutamatergic inputs leading to maladaptive synaptic plasticity
in the striatum is also a well-documented process underlying
LID genesis (6). At the striatal postsynaptic level, the interactions
of D1-type dopamine receptors with glutamate receptors,
particularly N-methyl-D-aspartate (NMDA) receptors and
metabotropic glutamate receptors, appear to be especially
relevant (6–9). Accordingly, oral administration of compounds
targeting NMDA receptors or specific subtypes of metabotropic
glutamate receptors (mGluR4 and mGluR5) has been challenged
in clinical practice (8). Currently, the oral administration
of amantadine, which is a non-competitive NMDA receptor
antagonist, represents the only recommended adjunct therapy
for reducing LIDs in patients with Parkinson’s disease (9).
However, its low therapeutic efficacy and various adverse effects
have limited its clinical use.
Applying the intracerebral brain infusion (iCBI) technique
for brain disorder treatment has a long history in experimental
and clinical studies on Parkinson’s disease [for examples, see
(10–12)]. Interestingly, Whone et al. (13) recently reported the
clinical use of a new and sophisticated drug delivery system
for intermittent intraputamenal infusion of the glial cell line-
derived neurotrophic factor in patients with Parkinson’s disease.
The present study was undertaken to examine if the continuous
intrastriatal infusion of memantine (MMT), which is a non-
competitive NMDA receptor antagonist and clinically used for
the treatment of dementia (14), through an iCBI system could
attenuate levodopa-induced AIMs and parkinsonian signs in
mice with hemiparkinsonism caused by 6-hydroxydopamine (6-
OHDA) lesions. Our results suggest that continuous intrastriatal
MMT infusion may represent a new therapeutic tool in treating
intractable LIDs associated with Parkinson’s disease.
MATERIALS AND METHODS
Animals
Adult male C57BL/6 mice aged 8–9 weeks (Nihon SLC,
Hamamatsu, Japan) were used. The mice were housed in a
controlled environment (25 ± 1◦C, 50 ± 10% humidity, and
12-h light/dark cycle) with access to food and tap water ad
libitum. All experimental procedures were approved by the
Institutional Animal Care and Use Committees of Tokushima
University, Japan.
Nigrostriatal 6-OHDA Lesion
Under anesthesia with N2O and isoflurane (Sigma-Aldrich,
St. Louis, MO, USA), the mice received an intraperitoneal
(i.p.) injection of desipramine hydrochloride (an inhibitor of
noradrenaline transporter, 1 mg/kg dissolved in 0.9 % saline,
Wako, Osaka, Japan) and pargyline hydrochloride (an inhibitor
of monoamine oxidase, 0.2 mg/kg dissolved in 0.9% saline,
Sigma-Aldrich, St. Louis, MO, USA). We used these inhibitors
for uptaking 6-OHDA selectively in brain dopaminergic neurons.
After 15min, they received stereotaxic injections of 6-OHDA
HCl (Sigma-Aldrich; 3 µg dissolved in 0.2 µl of 0.9% saline
containing 0.2% ascorbic acid) targeted into the medial forebrain
bundle (MFB) on the right side. The target coordinates (AP =
−1.2, L = +1.1, DV = +5.0) were according to the mouse
brain atlas (15). After a recovery of 2 weeks, the 6-OHDA-
lesioned mice, which showed over 80% of the spontaneous
ipsilateral rotation and apomorphine (0.5 mg/kg; Sigma-Aldrich)
injection-induced contralateral rotation (rotation check) at day 0
(Figure 1A), were processed for further studies.
Levodopa/Benserazide Treatments
Mice received intraperitoneal injections of levodopa (Sigma-
Aldrich; 15 mg/kg) dissolved in 0.9% saline containing 0.5%
carboxymethyl cellulose at 20min after i.p. injections of
benserazide HCl (Sigma-Aldrich; 12.5 mg/kg) dissolved in
0.9% saline.
Assessment of AIMs
AIM scoring was performed after the last levodopa injection
for 1min every 10min over a period of 150–180min, as
per our previous report (16). For the evaluation, each mouse
was placed in a 12-cm-diameter glass cylinder. The following
subtypes of AIMs were examined: axial (twisted posturing of
the neck and the upper body toward the contralateral side),
forelimb (jerky movements of the contralateral forelimb, and/or
grabbing movement of the contralateral paw), and orolingual
(jaw movements and tongue protrusion toward the contralateral
side). Each subtype was scored as follows: 0: absent; 1: occasional;
2: frequent; 3: continuous; and 4: continuous, not interrupted by
sensory stimuli.
Assessment of the Rotational Behaviors
Spontaneous rotational behaviors were assessed by measuring
systemic turns ipsilateral to the 6-OHDA lesion (17) 6 h after the
last levodopa administration. Apomorphine-induced rotations
contralateral to the 6-OHDA lesion were also measured 30min
after the apomorphine (0.5 mg/kg) administration.
Assessment of Hind Limb Stepping
Video-based analysis of the hind limb stepping in mice was
performed as reported previously (18). Mice were placed in 600-
ml beaker, and the spontaneous steps of their hind limbs were
video-recorded from the bottom for 5min. Each hind limb was
counted with a playback speed slowed to 0.3–0.5× using VLC
media player. Total hind limb steps were summed for both the
ipsilateral (intact) and contralateral (impaired) to the lesion side,
and the number of contralateral steps was calculated as % of
the total.
Placement of iCBI Devices and MMT
Administration
The iCBI devices equipped with the iPRECIOTM programmable
micro infusion pumps (Model SMP-300, Primetech Co.,
Tokyo, Japan) were implanted in the mice under anesthesia
with isoflurane (Sigma-Aldrich). The infusion cannulas were
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FIGURE 1 | Generation of dyskinetic mice for the intracerebral brain infusion (iCBI) experiments. (A) Timeline of experimentations (see “Materials and Methods”
section). Dyskinetic mice were implanted with programmable intracerebral brain infusion (iCBI) systems equipped with iPRECIOTM micro infusion pumps at day 28.
After a recovery of 3 days, they restarted receiving daily levodopa/benserazide treatments for the next 12 days. Simultaneously, MMT-treated dyskinetic mice received
continuous intrastriatal infusion of MMT 0.28 ng/µl at a flow rate of 1.0 µl/h for the first 3 days (days 31–33), MMT 1.12 ng/µl at a flow rate of 1.0 µl/h for the next 3
days (days 34–36), MMT 4.48 ng/µl at a flow rate of 1.0 µl/h for the next 3 days (days 37–39), and MMT 17.93 ng/µl a flow rate of 1.0 µl/h for the last 3 days (days
40–42). In parallel, PBS-treated dyskinetic mice received PBS under the same protocol. AIM scoring tests for MMT- or PBS-treated mice were done at days 33, 36,
39, and 42. (B) A representative photomicrograph of the striatum stained for tyrosine hydroxylase on the non-lesioned and lesioned (arrow) sides in mice with
6-OHDA-induced lesions. Scale bar = 2mm. (C) Quantification of the mean staining intensity for tyrosine hydroxylase (TH) in the dorsolateral striatum on the
non-lesioned (non-lesion) and lesioned (lesion) sides. In the Y-axis, the averaged pixel intensities in the measured area were expressed with arbitrary units. Data are
means ± SEM (n = 7). Paired two-tailed t-test: ***P < 0.001 vs. non-lesion. (D) Time course of the abnormal involuntary movements (AIMs) scored every 10min over
a period of 180min after the last levodopa administration in naïve mice and 6-hydroxydopamine (6-OHDA)-lesioned mice. Data are means ± SEM at each time point
(naïve mice, n = 10; 6-OHDA-lesioned mice, n = 14). (E) Spontaneous rotations ipsilateral to 6-OHDA-lesioned side percent of total in mice with or without 6-OHDA
lesions. 6-OHDA (–) (n = 6); 6-OHDA (+) (n = 6). Data are means ± SEM. **P < 0.01 vs. 6-OHDA (–); Mann-Whitney U-test. (F) Counts of apomorphine-induced
(Continued)
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FIGURE 1 | contralateral turns per 30min in mice with or without 6-OHDA lesions. 6-OHDA (–) (n = 6); 6-OHDA (+) (n = 6). Data are means ± SEM. **P < 0.01 vs.
naïve controls; Mann-Whitney U-test. (G) Counts of hind limb steps. Steps of the contralateral hind limb as % of the total count in the naïve controls (n = 6) and
Hemi-PD mice (n = 6). Data are means ± SEM. *P < 0.05 vs. naïve; Mann-Whitney U-test. (H–K) Schematic representation of the iCBI system, in which the pump
and tubing were implanted completely under the skin (H). The infusion cannula implanted into the dopamine-depleted striatum (I), together with the image of striatum
after fixation and removal of the cannula (J), and with a Nissl-stained image (K). Scale bars show 0.5mm in (J) and 100µm in (K).
implanted into the dopamine-depleted striatum at the stereotaxic
coordinates: AP = +0.3; L = +2.3; and DV = +3.0. MMT
HCl (Wako) was dissolved in 0.01M phosphate-buffered saline
at pH 7.2 (PBS), then applied for the infusion pumps. The used
concentrations of MMT were determined by the solubility to
PBS of MMT.
Immunohistochemistry and Digital Imaging
Immunostaining procedures and microscopic imaging
were previously described (19). The mice (n = 7) were
intraperitoneally injected with a lethal dose of pentobarbital
(Sigma-Aldrich), and transcardially perfused with cold saline,
followed by cold 4% paraformaldehyde in 0.1M phosphate
buffer (pH 7.2). The brains were removed, postfixed overnight
in the same fixative at 4◦C, and stored in a 10–30% sucrose
gradient in 0.01M phosphate buffered saline (pH 7.2) at 4◦C
for cryoprotection. Sections were cut on a cryostat at 16-µm
thickness and stored in PBS containing 0.05% NaN3 until use.
After blocking endogenous peroxidase activity, the free-floating
sections were incubated in PBS containing 3% bovine serum
albumin (PBS-BSA) for 60min. They were then incubated in
PBS-BSA with a rabbit polyclonal antibody tyrosine hydroxylase
(TH) (1:200,000) (19) for 18 h. The bound antibody was detected
using the Histofine Simple Stain Kit (Nichirei, Tokyo, Japan)
and the tyramide signal amplification system with Cyanine3
(Perkin Elmer, Shelton, CT, USA). For Nissl staining, sections
were stained with 0.1% cresyl violet acetate (Wako) dissolved
in distilled water. Digital microscopy images were captured
using an Olympus BX51 microscope (Olympus, Tokyo, Japan),
imported into Adobe Photoshop CS4, and digitally processed for
adjustments of contrast, brightness, and color balance.
Statistical Analysis
All analyses were expressed as group mean ± SEM. We used
paired two-tailed t-test or Mann-Whitney U-test for two-group
comparisons.Multiple comparisons were analyzed using analyses
of variance (ANOVA), followed by Bonferroni’s post-hoc tests for
pairwise comparisons. Statistical analyses were performed using
GraphPad Prism 7 Software (GraphPad Software Inc., San Diego,
CA, USA). P < 0.05 were considered statistically significant.
RESULTS
Generation and Characterization of a
Dyskinetic Mouse Model
The hemiparkinsonian mice were produced by unilateral
injections of 6-OHDA targeted into the right MFB (Figure 1A).
TH immunostaining revealed severe loss of striatal dopaminergic
afferents in the mice with 6-OHDA lesions (Figure 1B).
The quantifications revealed a >80% reduction of TH
immunoreactivity in the dorsal striatum on the 6-OHDA-
lesioned side compared to the non-lesioned side (Figure 1C;
P < 0.001, paired two-tailed t-test). After a period of 3 weeks
of levodopa/benserazide treatment, the AIM scoring tests
revealed that all 6-OHDA-lesioned mice manifested LIDs.
Figure 1D shows the time-sequential changes of AIMs in the
dyskinetic mice, which were maximal 10–60min after levodopa
administration (i.e., “ON” period) and almost disappeared
after 120 min.
Meanwhile, these dyskinetic mice also showed parkinsonian
signs 6 h after levodopa administration (i.e., “OFF” period). The
percentages of spontaneous rotations ipsilateral to the 6-OHDA-
lesioned side (or right side) relative to the total rotations were
significantly increased in mice with 6-OHDA lesions compared
to mice without 6-OHDA lesions (Figure 1E; P < 0.01, Mann-
Whitney U-test). Apomorphine-induced rotations contralateral
to the 6-OHDA-lesioned side were also significantly increased
in mice with 6-OHDA lesions as compared to mice without 6-
OHDA lesions (Figure 1F; P < 0.01, Mann-Whitney U-test).
Moreover, spontaneous use of hind limbs contralateral to the
6-OHDA-lesioned side was significantly decreased in mice with
6-OHDA lesions compared to mice without 6-OHDA lesions
(Figure 1G; P < 0.05, Mann-Whitney U-test).
Intrastriatal MMT Infusion Attenuates LIDs
in 6-OHDA-Lesioned Mice
To determine if intrastriatal MMT infusion could reduce LIDs
in the dyskinetic mice, we used the programmable and refillable
iCBI systems equipped with iPRECIOTM micro infusion pumps,
which make it possible to perform quantitative pharmacology
in single animals (20, 21). The iCBI devices (Figure 1H) with
the infusion cannulas implanted into the dopamine-depleted
striatum (Figures 1I–K) were placed at day 28 under the
experimental protocols (Figure 1A). No severe damage of the
tissue except for the cell clusters around the trace of infusion
cannula, which may represent gliosis (Figure 1K), was observed.
The levodopa/benserazide treatments were then restarted at day
31. Simultaneously, the MMT-treated dyskinetic mice received
continuous intrastriatal infusion ofMMT 0.28 ng/µl at a flow rate
of 1.0 µl/h for the first 3 days (days 31–33), MMT 1.12 ng/µl at
a flow rate of 1.0 µl/h for the next 3 days (days 34–36), MMT
4.48 ng/µl at a flow rate of 1.0 µl/h for the next 3 days (days
37–39), and MMT 17.93 ng/µl at a flow rate of 1.0 µl/h for the
last 3 days (days 40–42). In parallel, the PBS-treated dyskinetic
mice received PBS under the same protocol. Accordingly, the
AIM scoring tests for the MMT- or PBS-treated mice were done
at days 33 (Figure 2A), 36 (Figure 2B), 39 (Figure 2C), and 42
(Figure 2D). The two-way ANOVA on the total AIMs scores
(Figure 2E) revealed a significant effect of the MMT infusion
Frontiers in Neurology | www.frontiersin.org 4 December 2019 | Volume 10 | Article 1258
Ogawa et al. Intrastriatal Memantine Infusion
FIGURE 2 | Effects of intrastriatal memantine (MMT) infusion on levodopa-induced abnormal involuntary movements (AIMs) in dyskinetic mice. (A–D) Time-sequential
changes in the AIM scores every 10min over a period of 180min after the last levodopa administration in mice with intrastriatal infusion of PBS (n = 7) or MMT (n = 7)
at day 33 (B), day 36 (C), day 39 (D), and day 42 (E). (E) Total AIMs score in mice with intrastriatal infusion of PBS or MMT at days 33, 36, 39, and 42. Data are
means ± SEM. A significant effect of the MMT infusion treatment is found [two-way ANOVA: F (group×dose)3,48 = 5.856, P = 0.0017]. Bonferroni post-hoc test: PBS day
33 vs. MMT day 33, not significant (N.S.); PBS day 36 vs. MMT day 36, N.S.; and PBS day 42 vs. MMT day 42, ***P < 0.001. Significant differences in the severity of
AIMs at days 33, 36, and 42 are found (Bonferroni post-hoc test: MMT day 33 vs. MMT day 42, ##P < 0.01; MMT day 36 vs. MMT day 42, $$P < 0.01).
treatment [F(group×dose)3,48 = 5.856, P = 0.0017]. Compared to
PBS infusion, MMT infusion significantly reduced AIMs at day
42 (Bonferroni post-hoc test: PBS day 42 vs. MMT day 42, ∗∗∗P <
0.001). Moreover, a significant difference in the severity of AIMs
was found at days 33, 36, and 42 (Bonferroni post-hoc test: MMT
day 33 vs. MMT day 42, ##P < 0.01; MMT day 36 vs. MMT day
42, $$P < 0.01). Thus, intrastriatal MMT infusion significantly
attenuated levodopa-inducedAIMs in a dose-dependentmanner.
Intrastriatal MMT Infusion Attenuates
Parkinsonian Signs in 6-OHDA-Lesioned
Mice
We next determined if intrastriatal MMT infusion could also
affect parkinsonian signs in the dyskinetic mice. For this purpose,
behavioral tests for hemiparkinsonism were done 6 h after
the last levodopa/benserazide treatments at days 31 and 42
(Figure 1A). Notably, the two-way ANOVA on the percentage
of the spontaneous ipsilateral rotations relative to the total
rotations (Figure 3A) revealed a significant effect of the MMT
infusion treatment [F (group×dose)1,24 = 10.25, P = 0.0038]. MMT
infusion significantly normalized the rotational asymmetry at
day 42 (Bonferroni post-hoc test: MMT day 31 vs. MMT day
42, ∗∗P < 0.01; PBS day 42 vs. MMT day 42, ###P < 0.001).
The two-way ANOVA on the counts of apomorphine-induced
contralateral turns (Figure 3B) also showed a significant effect
of the MMT infusion treatment [F (group×dose)1,20 = 9.608, P =
0.0056]. MMT infusion significantly reversed the apomorphine-
induced rotational behaviors at day 42 (Bonferroni post-hoc
test: MMT day 31 vs. MMT day 42, ∗P < 0.05; PBS day
42 vs. MMT day 42, ##P < 0.01). The two-way ANOVA on
the counts of spontaneous contralateral hind limb stepping
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FIGURE 3 | Effects of intrastriatal memantine (MMT) infusion on parkinsonian signs in the dyskinetic mice. (A) Spontaneous rotations ipsilateral to the
6-OHDA-lesioned side percent of the total in the groups of PBS infusion at day 31 (PBS day 31, n = 7), MMT infusion at day 31 (MMT day 31, n = 7), PBS infusion
at day 42 (PBS day 42, n = 7), and MMT infusion at day 42 (MMT day 42, n = 7). Data are means ± SEM. A significant effect of MMT infusion [two-way ANOVA:
F (group×dose)1,24 = 10.25, P = 0.0038] is observed. Bonferroni post-hoc test: not significant (N.S.); MMT day 31 vs. MMT day 42, **P < 0.01; PBS day 42 vs. MMT day
42, ###P < 0.001. (B) Counts of apomorphine-induced contralateral turns per 30min in the groups of PBS day 31 (n = 6), MMT day 31 (n = 6), PBS day 42 (n =
6), and MMT day 42 (n = 6). Data are means ± SEM. A significant effect of MMT infusion [two-way ANOVA: F (group×dose)1,20 = 9.608, P = 0.0056] is found. Bonferroni
post-hoc test: not significant (N.S.); MMT day 31 vs. MMT day 42, *P < 0.05; PBS day 42 vs. MMT day 42, ###P < 0.001. (C) Spontaneous contralateral hind limb
steps as % of the total in PBS day 31 (n = 5), MMT day 31 (n = 5), PBS day 42 (n = 5), and MMT day 42 (n = 5). Data are means ± SEM. A significant effect of MMT
infusion [two-way ANOVA: F (group×dose)1,16 = 7.891, P = 0.0126] is found. Bonferroni post-hoc test: not significant (N.S.); MMT day 31 vs. MMT day 42, ***P < 0.001;
PBS day 42 vs. MMT day 42, #P < 0.05. (D) Total number of turns in spontaneous rotations summed with both ipsi- and contra-lateral directions. Data are means
± SEM. No significance was observed [two-way ANOVA: F (group×dose)1,24 = 6.507, P = 0.0434]. (E) Total number of steps summed with both ipsi- and contra-lateral
hind limbs. Data are means ± SEM. No significance was observed [two-way ANOVA: F (group×dose)1,16 = 0.3957, P = 0.5634].
(Figure 3C) also showed a significant effect of the MMT infusion
treatment [F(group×dose)1,16 = 7.891, P = 0.0126]. MMT infusion
significantly normalized the % of contralateral hind limb steps at
day 42 (Bonferroni post-hoc test: MMT day 31 vs. MMT day 42,
∗∗∗P < 0.001; PBS day 42 vs. MMT day 42, #P < 0.05). There was
no significant difference between PBS and MMT groups in the
total number of spontaneous turns (Figure 3D) nor of hind limb
steps (Figure 3E). Thus, MMT infusion significantly improved
not only AIMs but also parkinsonian signs in dyskinetic mice.
DISCUSSION
The long-term and repeated pharmacological overactivation
of striatal dopamine receptors, which leads to an altered
glutamatergic transmission at several nodes of the corticobasal
ganglia circuit, is generally viewed as the principal cause for
LIDs in patients with advanced Parkinson’s disease. We provide
herein experimental evidence that intrastriatal MMT infusion
exerts therapeutic effects on both levodopa-induced AIMs and
parkinsonian signs in mice with hemiparkinsonism caused by 6-
OHDA. Although there is a difficulty to distinguish improvement
of akinesia from induction of dyskinesia in rodent models of
Parkinson’s disease, and further studies using primate models
are essentially required, our finding in this study corroborates
the general thought that the overactivation of striatal NMDA
receptors, which mediate a slow, Ca2+-permeable component of
excitatory synaptic transmission (22), might generate LIDs and
“OFF”-period motor deficits in Parkinson’s disease (4, 5, 7, 23).
Indeed, clinical observations have shown the positive therapeutic
potential of the NMDA receptor antagonists amantadine (24)
and MMT (25–28) in the treatment of LIDs and parkinsonian
symptoms in patients with Parkinson’s disease. However,
the oral administration of NMDA antagonists, particularly
amantadine, causes considerable noncerebral side effects, such
as cardiovascular, gastrointestinal, and skin reactions (8, 26). It
Frontiers in Neurology | www.frontiersin.org 6 December 2019 | Volume 10 | Article 1258
Ogawa et al. Intrastriatal Memantine Infusion
also incites cerebral adverse effects of nonstriatal origin, such
as psychosis, hallucinations, and learning and memory deficit,
because of the wide distribution of NMDA receptors in the brain
(29). Considering the structural similarity between amantadine
and MMT, these central and systemic side effects limit the usable
dose of NMDA antagonists and reduce their clinical impact (30).
A recent report of meta-analysis comparing multiple medicines
in Alzheimer’s disease patients showed that oral administration
of MMT is safe enough (31). However, it is not approved for
the treatment of Parkinson’s disease patients yet. In a previous
study, although single injection of MMT or amantadine did
reduce LIDs in the 6-OHDA-lesioned rats, this antidyskinetic
effect has disappeared by subchronic administration for a few
days (32). It indicates that drug tolerance toMMT or amantadine
developed during the treatment. A clinical study also reported
that the beneficial effect of amantadine on dyskinesia was lost
within 8 months (33). The underlying mechanism of MMT or
amantadine tolerance, including whether it is caused by central
or peripheral reasons, is still unknown. Given that the drug
tolerance by repeated oral or systemic administration limits
the therapeutic efficacy, it is worth developing an alternative
drug delivery system, such as iCBI, despite of the risks, such as
complications accompanying physical invasion.
The iCBI system makes it possible to deliver appropriately
adjusted doses of desired drugs into specific brain regions.
Therefore, intrastriatal infusion of NMDA antagonists through
the iCBI system may provide higher therapeutic efficacy while
reducing the adverse side effects of their oral or systemic
administration in the treatment of LIDs. For the issue of drug
tolerance, longer iCBI treatment of NMDA antagonists than this
study should be examined. With the hope that programmable
iCBI devices with a clinical application can be developed,
we suggest the pharmacological deep-brain modulation as an
alternative therapeutic approach for the treatment of Parkinson’s
disease and, potentially, other movement disorders.
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